STERIS plc Enters Material Definitive Agreement
Ticker: STE · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1757898
Sentiment: neutral
Topics: debt, agreement
TL;DR
STERIS plc just signed a big deal for its 2031 and 2051 notes.
AI Summary
On April 10, 2024, STERIS plc entered into a Material Definitive Agreement related to its STETwo700SeniorNotesDue2031 and Two700SeniorNotesDue2051. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
Why It Matters
This filing indicates a significant financial transaction or agreement for STERIS plc, potentially impacting its debt structure and future financial obligations.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new financial risks or obligations for a company.
Key Players & Entities
- STERIS plc (company) — Registrant
- STETwo700SeniorNotesDue2031 (company) — Debt Instrument
- Two700SeniorNotesDue2051 (company) — Debt Instrument
- April 10, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by STERIS plc?
The filing indicates the agreement is related to its STETwo700SeniorNotesDue2031 and Two700SeniorNotesDue2051.
When did STERIS plc enter into this Material Definitive Agreement?
The earliest event reported in the filing occurred on April 10, 2024.
What other information is included in this 8-K filing?
The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
What is STERIS plc's country of incorporation?
STERIS plc is incorporated in Ireland.
What is STERIS plc's IRS Employer Identification Number?
STERIS plc's IRS Employer Identification Number is 98-1455064.
Filing Stats: 1,948 words · 8 min read · ~6 pages · Grade level 19.3 · Accepted 2024-04-11 07:22:35
Key Financial Figures
- $0.001 — e on which registered Ordinary Shares. $0.001 par value STE New York Stock Exchan
- $787.5 million — e price for the Transaction consists of $787.5 million in cash, subject to customary adjustmen
- $12.5 million — ry adjustments, and up to an additional $12.5 million in contingent payment payable to Seller
- $35 million — ired to pay Seller a termination fee of $35 million. Item7.01 Regulation FD Disclosure.
Filing Documents
- d752903d8k.htm (8-K) — 38KB
- d752903dex991.htm (EX-99.1) — 14KB
- 0001193125-24-092481.txt ( ) — 220KB
- ste-20240410.xsd (EX-101.SCH) — 4KB
- ste-20240410_def.xml (EX-101.DEF) — 13KB
- ste-20240410_lab.xml (EX-101.LAB) — 22KB
- ste-20240410_pre.xml (EX-101.PRE) — 14KB
- d752903d8k_htm.xml (XML) — 7KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release, dated April 11, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts," "outlook," "impact," "potential," "confidence," "improve," "optimistic," "deliver," "orders," "backlog," "comfortable," "trend" and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or interpretation thereof. Other risk factors are described in STERIS's other securities filings, including Item 1A of our Annual Report on Form 10-K for the year ended March 31, 2023. Many of these important factors are outside of STERIS's control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in STERIS's securities filings or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost reductions, business strategies, earnings or revenue trends or future financial results. References to products are
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STERIS plc By /s/ J. Adam Zangerle J. Adam Zangerle Senior Vice President, General Counsel and Company Secretary Dated: April 11, 2024